Matches in Wikidata for { <http://www.wikidata.org/entity/Q58614874> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- Q58614874 description "article scientifique publié en 2007" @default.
- Q58614874 description "artículu científicu espublizáu en xunetu de 2007" @default.
- Q58614874 description "im August 2007 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58614874 description "scientific article published on 02 July 2007" @default.
- Q58614874 description "wetenschappelijk artikel" @default.
- Q58614874 description "наукова стаття, опублікована в серпні 2007" @default.
- Q58614874 name "Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer" @default.
- Q58614874 name "Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer" @default.
- Q58614874 type Item @default.
- Q58614874 label "Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer" @default.
- Q58614874 label "Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer" @default.
- Q58614874 prefLabel "Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer" @default.
- Q58614874 prefLabel "Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer" @default.
- Q58614874 P1433 Q58614874-EDFE3A55-2358-414A-88F8-F268C6935868 @default.
- Q58614874 P1476 Q58614874-6FE10C33-FA6E-454C-A256-40162A9CFD6C @default.
- Q58614874 P2093 Q58614874-04132BCB-8BE8-49BF-B008-867ECD514FD6 @default.
- Q58614874 P2093 Q58614874-0C18C764-0C91-4138-B2FF-F3E8D13636FE @default.
- Q58614874 P2093 Q58614874-1A6ECA4A-A094-42CE-AA03-C49941133A14 @default.
- Q58614874 P2093 Q58614874-2658B1FD-E79A-41BE-B87E-EE455C71387E @default.
- Q58614874 P2093 Q58614874-49094CFF-5080-4BE6-BAE0-3558E9640DCA @default.
- Q58614874 P2093 Q58614874-4AA0A77A-838E-43FC-A4DD-529662C9462D @default.
- Q58614874 P2093 Q58614874-6454593C-4C6F-4F82-BB4F-B3B988654B6D @default.
- Q58614874 P2093 Q58614874-667626E9-80DC-47E2-BA80-EA20D0E08701 @default.
- Q58614874 P2093 Q58614874-7ED3EE2A-8EA3-4202-9058-6DCA254D746B @default.
- Q58614874 P2093 Q58614874-AD0C7067-EE8C-4D90-9244-0F3B483374B1 @default.
- Q58614874 P2093 Q58614874-D5ED0E30-48DA-4939-A58C-809DF3822D7C @default.
- Q58614874 P304 Q58614874-96BD5516-78B2-4FBF-8D35-2A2F16B356B5 @default.
- Q58614874 P31 Q58614874-C6824B29-46B6-43D2-B91D-107A85FB81E2 @default.
- Q58614874 P356 Q58614874-D93D8174-34A6-4F8F-9FC5-52672C9BF6E4 @default.
- Q58614874 P407 Q58614874-4FAA6101-EB95-44A2-9350-6828BBC7C046 @default.
- Q58614874 P433 Q58614874-75254D10-6305-4C30-BA30-485F308999DB @default.
- Q58614874 P478 Q58614874-67C5FFFC-D848-4256-AFFC-930451C99294 @default.
- Q58614874 P50 Q58614874-434CDF05-0824-4521-8079-0CE5B2E71A45 @default.
- Q58614874 P50 Q58614874-6C4A2FC9-01F8-46A5-9261-7F0B3A698C9E @default.
- Q58614874 P50 Q58614874-8A34A627-DB66-477E-91D9-DCB3AF8B254B @default.
- Q58614874 P50 Q58614874-BD9656C8-422B-4F9B-934B-E62E81947284 @default.
- Q58614874 P50 Q58614874-D7F964DF-0C29-446E-A43F-E853B6238D72 @default.
- Q58614874 P50 Q58614874-FA0D1917-C56E-4513-8AAA-A2EDEED2E6A7 @default.
- Q58614874 P577 Q58614874-FF73BEFD-86F9-4A09-9A91-F0257EBFE835 @default.
- Q58614874 P698 Q58614874-68B0925E-C5BC-4012-BDC3-AB8046848482 @default.
- Q58614874 P921 Q58614874-1F3A26B6-AF10-4733-8E48-4C0E2F0FC914 @default.
- Q58614874 P921 Q58614874-2272A47D-5A20-4D38-AE25-BE3C066EAD7D @default.
- Q58614874 P921 Q58614874-82ECAFC6-9290-4C3C-9AA0-8AB5ED0C45C6 @default.
- Q58614874 P921 Q58614874-8B84E156-C065-4DE9-AF13-EE0218010BE9 @default.
- Q58614874 P356 JCO.2006.08.9102 @default.
- Q58614874 P698 17606975 @default.
- Q58614874 P1433 Q400292 @default.
- Q58614874 P1476 "Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer" @default.
- Q58614874 P2093 "Craig A Bunnell" @default.
- Q58614874 P2093 "David Lebwohl" @default.
- Q58614874 P2093 "Edgardo Rivera" @default.
- Q58614874 P2093 "Eva Thomas" @default.
- Q58614874 P2093 "Howard A Burris" @default.
- Q58614874 P2093 "José Baselga" @default.
- Q58614874 P2093 "Judith Klimovsky" @default.
- Q58614874 P2093 "Monica Fornier" @default.
- Q58614874 P2093 "Patrice Viens" @default.
- Q58614874 P2093 "Pierre Fumoleau" @default.
- Q58614874 P2093 "Valerie Poulart" @default.
- Q58614874 P304 "3399-3406" @default.
- Q58614874 P31 Q13442814 @default.
- Q58614874 P356 "10.1200/JCO.2006.08.9102" @default.
- Q58614874 P407 Q1860 @default.
- Q58614874 P433 "23" @default.
- Q58614874 P478 "25" @default.
- Q58614874 P50 Q37387600 @default.
- Q58614874 P50 Q40149511 @default.
- Q58614874 P50 Q56550967 @default.
- Q58614874 P50 Q56798835 @default.
- Q58614874 P50 Q58283362 @default.
- Q58614874 P50 Q67755317 @default.
- Q58614874 P577 "2007-07-02T00:00:00Z" @default.
- Q58614874 P698 "17606975" @default.
- Q58614874 P921 Q11711607 @default.
- Q58614874 P921 Q12859063 @default.
- Q58614874 P921 Q181600 @default.
- Q58614874 P921 Q42824440 @default.